CalciMedica is trading at $0.65, reflecting a -5.45% change, with no clear catalyst identified.
- No new August 10, 2026 company announcement surfaced in reliable search results; the latest identified major update was July 29 FDA alignment on Auxora’s acute-pancreatitis Phase 2b design.
- Major indexes are broadly flat, so broader-market weakness does not clearly explain the move.
- Investors may be positioning ahead of the expected Q2 2026 earnings update, but evidence does not establish that as the direct cause.